Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Carbohydr Polym ; 254: 117399, 2021 Feb 15.
Article in English | MEDLINE | ID: mdl-33357889

ABSTRACT

Starch based materials are attractive bio-based alternative to fully synthetic polymers. Native starch has however limited thermoprocessability and properties and must be modified. In order to improve the properties of starch-graft-poly(butyl-acrylate-co-styrene) copolymers via a process as green as possible, we report herein a new method for the dual functionalization of the polysaccharide via a one pot one step reaction in aqueous medium combining free radical polymerizations and ring-opening chemistry. Poly(butyl acrylate) or poly(butyl acrylate-co-styrene) (ca. 60 000 g/mol) and oligo(ε-caprolactone) were grafted on starch with a grafting percentage up to 75 %. The copolymers show two glass transition temperatures: one around 55-60 °C related to starch and a second attributed to the grafted vinyl polymers, from -46 °C to 20 °C depending on butyl acrylate/styrene ratio. The resulting dual functionalized materials exhibit excellent mechanical properties, with elongation at break in the range 20-210 %, while single functionalized starch shows less than 5 %.


Subject(s)
Polymerization , Starch/chemistry , Water/chemistry , Acrylates/chemistry , Acrylic Resins/chemistry , Caproates/chemistry , Free Radicals/chemistry , Lactones/chemistry , Polystyrenes/chemistry , Transition Temperature , Vinyl Compounds/chemistry
2.
Bioorg Med Chem ; 26(18): 5169-5180, 2018 10 01.
Article in English | MEDLINE | ID: mdl-30253886

ABSTRACT

Free fatty acid-2 (FFA2) receptor is a G-protein coupled receptor of interest in the development of therapeutics in metabolic and inflammatory disease areas. The discovery and optimization of an N-thiazolylamide carboxylic acid FFA2 agonist scaffold is described. Dual key objectives were to i) evaluate the potential of this scaffold for lead optimization in particular with respect to safety de-risking physicochemical properties, i.e. lipophilicity and aromatic content, and ii) to demonstrate the utility of selected lead analogues from this scaffold in a pertinent in vivo model such as oral glucose tolerance test (OGTT). As such, a concomitant improvement in bioactivity together with lipophilic ligand efficiency (LLE) and fraction sp3 content (Fsp3) parameters guided these efforts. Compound 10 was advanced into studies in mice on the basis of its optimized profile vs initial lead 1 (ΔLLE = 0.3, ΔFsp3 = 0.24). Although active in OGTT, 10 also displayed similar activity in the FFA2-knockout mice. Given this off-target OGTT effect, we discontinued development of this FFA2 agonist scaffold.


Subject(s)
Diabetes Mellitus, Experimental/drug therapy , Disease Models, Animal , Drug Discovery , Receptors, Cell Surface/agonists , Thiazoles/pharmacology , Animals , Dose-Response Relationship, Drug , Humans , Mice , Mice, Knockout , Molecular Structure , Rats , Receptors, Cell Surface/deficiency , Receptors, Cell Surface/metabolism , Structure-Activity Relationship , Thiazoles/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL